SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
-$0.02 today
- Market cap
- $288.28M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
Volume 0.89M
Average 0.76M
SABS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
SAB Biotherapeutics, Inc.NASDAQ: SABS
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 123.9% from a year ago
Cash & equivalents stood at $8.27M at the end of Q2 FY2026, up 123.9% from a year earlier and down 59.7% from the prior quarter. Over 3 fiscal years it compounded at -11.3% a year.
Context
- Cash & equivalents amounted to 3.5% of total assets at the end of Q2 FY2026, down 8.8 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +123.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- +18.0%
- 4-year CAGR
- -25.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | +18.0% |
| FY2024 | 2024-12-31 | 8.9M | -84.3% |
| FY2023 | 2023-12-31 | 56.57M | +275.9% |
| FY2022 | 2022-12-31 | 15.05M | -54.7% |
| FY2021 | 2021-12-31 | 33.21M | — |
Cash & Equivalents vs competitors
How SABS compares with its peers on the latest reported figures
- SABS's Jun 2026 cash & equivalents of $8.27M is the lowest of the 5 companies compared; the peer median is $35.68M.
- Its year-over-year change of +123.9% is the 2nd highest of 5, against a peer median of -3.4%.
- Cash & equivalents amounts to 3.5% of total assets for SABS, versus a peer median of 57.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.49M | +167.6% | -9.9% | 61.1% | |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Mar 2026 | $20.6M | -30.4% | -4.2% | 53.1% | |
| Mar 2026 | $17.48M | +15.7% | +17.7% | 12.4% | |
| Jun 2026 | $8.27M | +123.9% | -11.3% | 3.5% | |
| Peer median (excluding SABS) | $35.68M | -3.4% | -0.5% | 57.1% | |
Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33.21M | 15.05M | 56.57M | 8.9M | 10.5M |
| Short-term Investments | 0 | 0 | 0 | 11.86M | 86.09M |
| Net Receivables | 8.01M | 5.56M | 0 | 54.96K | 946.78K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.34M | 0 | 0 | 2.98M | 3.51M |
| Total Current Assets | 50.19M | 22.1M | 58.91M | 23.79M | 101.05M |
| Property, Plant & Equipment (Net) | 30.95M | 28.34M | 24.68M | 19.92M | 19.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 46.89M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 467.69K | 350.23K | 482.1K | 5.46M |
| Total Non-current Assets | 30.95M | 28.81M | 25.03M | 20.4M | 71.76M |
| Total Assets | 81.14M | 50.9M | 83.94M | 44.2M | 172.81M |
| Account Payables | 4.46M | 3.68M | 945.93K | 1.69M | 3.15M |
| Short-term Debt | 1.8M | 772.67K | 1.05M | 275.85K | 951.37K |
| Tax Payables | 216.25K | 50K | 40K | 0 | 0 |
| Deferred Revenue | 100K | 0 | 1.32M | 0 | 0 |
| Other Current Liabilities | 8.7M | 8.1M | 4.49M | 0 | 1.55M |
| Total Current Liabilities | 26.46M | 14.99M | 10.81M | 7.98M | 10.68M |
| Long-term Debt | 0 | 541.64K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.72M | 320.93K | 11.77M | 6.39M | 5.64M |
| Total Non-current Liabilities | 16.14M | 4.85M | 15.83M | 10.25M | 10.63M |
| Total Liabilities | 42.59M | 19.85M | 26.64M | 18.23M | 21.32M |
| Common Stock | 4.35K | 5.09K | 929 | 935 | 4.77K |
| Retained Earnings | (29.13M) | (47.87M) | (90.06M) | (124.17M) | (110.9M) |
| Accumulated OCI | 0 | 0 | 26.42K | (135.41K) | 186.51K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.55M | 31.06M | 57.3M | 25.97M | 151.49M |
| Total Debt | 8.52M | 5.93M | 5.91M | 4.67M | 5.95M |
| Net Debt | (24.69M) | (9.12M) | (50.66M) | (4.23M) | (4.55M) |
SAB Biotherapeutics, Inc.
NASDAQ:SABS
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.